Finerenone in Type 1 Diabetes and Chronic Kidney Disease.

Saved in:
Bibliographic Details
Title: Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Authors: Heerspink HJL; George Institute for Global Health, University of New South Wales, Sydney.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Birkenfeld AL; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.; German Center for Diabetes Research, Neuherberg, Germany.; Internal Medicine IV, Department of Endocrinology, Diabetology, and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany., Cherney DZI; Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto., Colhoun HM; Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh., Groop PH; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki., Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Mathieu C; Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium., Pratley RE; AdventHealth Translational Research Institute, Orlando, FL., Rosas SE; Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen., Skyler JS; Department of Medicine and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami., Tuttle KR; Providence Inland Northwest Health, University of Washington School of Medicine, Spokane., Lawatscheck R; Cardiology and Nephrology Clinical Development, Bayer, Berlin., Brinker M; Cardiology and Nephrology Clinical Development, Bayer, Wuppertal, Germany., Scheerer MF; Medical Affairs and Pharmacovigilance, Pharmaceuticals, TA CardioRenal and Heart Disease, Bayer, Berlin., Russell J; Bayer, Reading, United Kingdom., Schloemer P; Clinical Statistics and Analytics, Bayer, Berlin., McGill JB; Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine in St. Louis, St. Louis.
Corporate Authors: FINE-ONE Investigators
Source: The New England journal of medicine [N Engl J Med] 2026 Mar 05; Vol. 394 (10), pp. 947-957.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1533-4406
DOI:10.1056/NEJMoa2512854